GnRH-antagonists in reproductive medicine

Suppression of sex steroid production based on desensitisation and down-regulation of pituitary gonadotropin-releasing hormone (GnRH)-receptors by agonistic GnRH-analogues resulting in the blockage of gonadotropin release from the anterior pituitary gland is a well-established approach in a variety of clinical conditions. Antagonistic analogues of GnRH exert their effect by competing with endogenous GnRH for pituitary binding sites. Because of the lack of any intrinsic activity of these compounds, the characteristic initial ‘flare-up’ effect of GnRH-agonist administration is absent. A more rapid suppression of gonadotropin release from the pituitary gland can be achieved, enabling shorter treatment regimes in ovarian hyperstimulation for assisted reproduction. As yet, GnRH-antagonists have attained market approval only for the indication of premature luteinizing hormone (LH) surge prevention in controlled ovarian hyperstimulation and palliative treatment of advanced prostatic cancer. However, GnRH-antagonists may be useful in a variety of other malignant and non-malignant indications where rapid sex steroid suppression is desired, such as uterine leiomyomas, endometriosis, gynaecological cancers or benign prostatic hyperplasia. In the context of infertility treatment, available data on the application of GnRH-antagonists in the treatment of endometriosis and uterine leiomyomas are reviewed. Similar content being viewed by others

Al-Inany H, Aboulghar M (2003) Gonadotrophin-releasing hormone antagonists for assisted conception (Cochrane Review). In: The Cochrane Library, Issue1. Update Software, Oxford Barbieri RL (1998) Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment. J Reprod Med 43:287–292 Cedars MI, Lu JK, Meldrum DR, Judd HL (1990) Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol 75:641–645 Compston JE, Yamaguchi K, Croucher PI, Garrahan NJ, Lindsay PC, Shaw RW (1995) The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 16:261–267 Conn PM, Crowley WF (1991) Gonadotrophin-releasing hormone and its analogues. New Engl J Med 324:93–103 Clayton RN (1989) Gonadotrophin-releasing hormone: its actions and receptors. J Endocrinol 120:11–19 De Blok S, Oberye J (2001) Rapid reduction of leiomyoma volume during treatment with the GnRH-antagonist ganirelix. Gynecol Endocrinol 15:22 De Reijke TM, Burk K, Kurth KH (1996) Clinical and endocrinological results of patients treated with LHRH antagonist (cetrorelix). Eur Urol 30:245 Dlugi AM, Miller JD, Knittel J (1990) Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomised, placebo-controlled, double-blind study. Fertil Steril 54:419–427 Duijkers IJ, Klipping C, Willemsen WN, Krone D, Schneider E, Niebch G, Hermann R. (1998) Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod 13:2392–2398 Erb K, Klipping C, Duijkers I, Pechstein B, Schueler A, Hermann R (2001) Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. Fertil Steril 75:316–323 Felberbaum RE, Germer U, Ludwig M, Riethmuller-Winzen H, Heise S, Buttge I, Bauer O, Reissmann T, Engel J, Diedrich K (1998) Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod 13:1660–1668 Felberbaum RE, Kupker W, Krapp M, Gehl B, Ludwig M, Diedrich K (2003) Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide). Reprod Biomed Online 3:14–18 Felberbaum R, Kuepker W, Finas D, Krapp M, Gehl B, Altgassen C, Friedrich M, Diedrich K (2004) Uterine leiomyoma. Endocrine surgery: organ-preserving treatment options. Gynaekologische Endokrinologie 2:6–10 Friedman AJ (1993) Use of gonadotropin-releasing hormone agonists before myomectomy. Clin Obstet Gynecol 36:650–659 Garnick MB, Campion M (2000) Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol 4:275–277 Gonzalez-Barcena D, Alvarez RB, Ochoa EP, Cornejo IC, Comaru-Schally AM, Schally AV, Engel J, Reissmann T, Riethmuller-Winzen H (1997) Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 12:2028–2035 Hazum E, Keinan D (1985) Gonadotropin releasing hormone activation is mediated by dimerization of occupied receptors. Biochem Biophys Res Comm 133:449–456 Hornstein MD, Yuzpe AA, Burry KA, Heinrich LR, Buttram VL Jr, Orwoll ES (1995) Prospective randomised double-blind trial of 3 vs. 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril 63:955–962 Hornstein MD, Surrey ES, Weisberg GW, Casino LA (1998) Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 91:16–24 Horvath JE, Toller GL, Schally AV, Bajo AM, Groot K (2004) Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Proc Natl Acad Sci USA 101:4996–5001 Kiilholma P, Tuimala R, Kivinen S, Korhonen M, Hagman E (1995) Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertil Steril 64:903–908 Kettel LM, Murphy AA, Morales AJ, Rivier J, Vale W, Yen SS (1993) Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril 60:642–646 Koch M, Steidle C, Brosman S, Centeno A, Gaylis F, Campion M, Garnick MB (2003) An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology 62:877–882 Kuepker W, Schultze-Mosgau A, Diedrich K (1998) Paracrine changes in the peritoneal environment of women with endometriosis. Hum Rep Update 4:719–723 Kupker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K (2002) Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 5:12–16 Lethaby A, Vollenhoven B, Sowter M (2002) Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG 109:1097–1108 Martha PM, Gray ME, Campion M, Kuca B and Garnick MB (1999) Prolonges suppression of circulating estrogen levels without an initial hormonal flare using abarelix-depot, a pure GnRH-antagonist in women with endometriosis. Fertil Steril 72(Suppl 1):S210–(P-375) McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Garnick MB (2001) Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58:756–761 Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Niebch G, Derendorf H (2000) Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. Clin Pharmacol Ther 68:617–625 Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Locher M, Derendorf H (2003) Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. J Clin Pharmacol 43:243–251 Oberye JJ, Mannaerts BM, Kleijn HJ, Timmer CJ (1999a) Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril 72:1001–1005 Oberye JJ, Mannaerts BM, Huisman JA, Timmer CJ (1999b) Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril 72:1006–1012 Rein MS, Friedman AJ, Stuart JM, MacLaughlin DT (1990) Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril 53:1018–1023 Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV (1995) Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 10:1974–1981 Rivier J (1993) Novel antagonists of GnRH: a compendium of their physiochemical properties, activities, relative potencies and efficacy in humans. In: Lunenfeld B, Insler V (eds) GnRH analogues—the state of the art 1993. The Parthenon Publishing Group, London, pp 13 Smith MA, Perrin MH, Vale WW (1983) Desensitization of cultured pituitary cells to gonadotropin-releasing hormone: evidence for a post-receptor mechanism. Mol Cell Endocrinol 30:85–96 Surrey ES, Voigt B, Fournet N, Judd HL (1995) Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone “add-back” therapy. Fertil Steril 63:747–755 Tahara M, Matsuoka T, Yokoi T, Tasaka K, Kurachi H, Murata Y (2000) Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy (“draw-back” therapy). Fertil Steril 73:799–804 Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB (2001) The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 165:1585–1589 Wong SL, Lau DT, Baughman SA, Menchaca D, Garnick MB (2003) Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. Clin Pharmacol Ther 73:304–311 Yano T, Minaguchi H, Taketani Y, Mori H, Terakawa N (2001) Cetrorelix in the treatment of uterine leiomyomas. Gynecol Endocrinol 15(Suppl 1):46 Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Griesinger, G., Felberbaum, R. & Diedrich, K. GnRH-antagonists in reproductive medicine. Arch Gynecol Obstet 273, 71–78 (2005). https://doi.org/10.1007/s00404-005-0021-2 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s00404-005-0021-2